Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar;59(3):1925-1937.
doi: 10.1007/s12035-022-02739-0. Epub 2022 Jan 15.

N6-methyladenosine and Neurological Diseases

Nan Zhang #  1 , Chunhong Ding #  1 , Yuxin Zuo  1 , Yu Peng  1 , Lielian Zuo  2
Affiliations
Review

N6-methyladenosine and Neurological Diseases

Nan Zhang et al. Mol Neurobiol. 2022 Mar.

Abstract

N6-methyladenosine (m6A) is a dynamic reversible methylation modification of the adenosine N6 position and is the most common chemical epigenetic modification among mRNA post-transcriptional modifications, including methylation, demethylation, and recognition. Post-transcriptional modification involves multiple protein molecules, including METTL3, METTL14, WTAP, KIAA1429, ALKBH5, YTHDF1/2/3, and YTHDC1/2. m6A-related proteins are expressed in almost all cells. However, the abnormal expression of m6A-related proteins may occur in the nervous system, thereby affecting neuritogenesis, brain volume, learning and memory, memory formation and consolidation, etc., and is implicated in the development of diseases, such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, depression, epilepsy, and brain tumors. This review focuses on the functions of m6A in the development of central nervous system diseases, thus contributing to a deeper understanding of disease pathogenesis and providing potential clinical therapeutic targets for neurological diseases.

Keywords: Alzheimer’s disease; Epigenetic modifications; N6-methyladenosine (m6A); Neurological diseases; Parkinson’s disease.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tang Y, Chen K, Song B, Ma J, Wu X, Xu Q, Wei Z, Su J, Liu G, Rong R, Lu Z, de Magalhaes JP, Rigden DJ, Meng J (2021) m6A-Atlas: a comprehensive knowledgebase for unraveling the N6-methyladenosine (m6A) epitranscriptome. Nucleic Acids Res 49(D1):D134–D143. https://doi.org/10.1093/nar/gkaa692 - DOI - PubMed
    1. Wu Z, Shi Y, Lu M, Song M, Yu Z, Wang J, Wang S, Ren J, Yang YG, Liu GH, Zhang W, Ci W, Qu J (2020) METTL3 counteracts premature aging via m6A-dependent stabilization of MIS12 mRNA. Nucleic Acids Res 48(19):11083–11096. https://doi.org/10.1093/nar/gkaa816 - DOI - PubMed - PMC
    1. Zhang Z, Wang Q, Zhang M, Zhang W, Zhao L, Yang C, Wang B, Jiang K, Ye Y, Shen Z, Wang S (2021) Comprehensive analysis of the transcriptome-wide m6A methylome in colorectal cancer by MeRIP sequencing. Epigenetics 16(4):425–435. https://doi.org/10.1080/15592294.2020.1805684 - DOI - PubMed
    1. Rasheed M, Liang J, Wang C, Deng Y, Chen Z. Epigenetic regulation of neuroinflammation in Parkinson’s disease. Int J Mol Sci. 2021;22(9). https://doi.org/10.3390/ijms22094956
    1. Livneh I, Moshitch-Moshkovitz S, Amariglio N, Rechavi G, Dominissini D (2019) The m6A epitranscriptome: transcriptome plasticity in brain development and function. Nat Rev Neurosci 21(1):36–51. https://doi.org/10.1038/s41583-019-0244-z - DOI - PubMed

LinkOut - more resources